The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia

Gain-of-function mutations of isocitrate dehydrogenases 1/2 (IDH1/2) play crucial roles in the development and progression of acute myeloid leukemia (AML), which provide promising therapeutic targets. Two small molecular inhibitors, ivosidenib and enasidenib have been approved for the treatment of I...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Xiaomei, Pei, Han Zhong, Li, Tianwen, Huang, Junbin, Guo, Yao, Zhao, Yuming, Yang, Ming, Zhang, Dengyang, Chang, Zhiguang, Zhang, Qi, Yu, Liuting, He, Chunxiao, Zhang, Liqing, Pan, Yihang, Chen, Chun, Chen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260655/
https://www.ncbi.nlm.nih.gov/pubmed/35814406
http://dx.doi.org/10.3389/fonc.2022.931462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260655/
https://www.ncbi.nlm.nih.gov/pubmed/35814406
http://dx.doi.org/10.3389/fonc.2022.931462

Ejemplares similares